Caterpillar stock drifts into year-end as Fed minutes loom and trading stays thin
29 December 2025
1 min read

Caterpillar stock drifts into year-end as Fed minutes loom and trading stays thin

NEW YORK, December 28, 2025, 22:48 ET — Market closed

  • Caterpillar shares closed down 0.13% on Friday at $583.00 in muted post-Christmas trade. FinancialContent
  • Wall Street finished slightly lower in a light-volume session, leaving investors scanning for the next catalyst into year-end. Reuters
  • Traders are watching Tuesday’s Fed minutes and late-December market rotation beyond big tech. Reuters

Caterpillar Inc shares ended Friday slightly lower, closing down 0.13% at $583.00 as trading stayed subdued ahead of the final sessions of 2025. FinancialContent

The heavy-equipment maker is widely watched as a read on cyclical demand, and the muted move comes as investors head into year-end looking for fresh direction from rates and broader market leadership. Reuters

Minutes from the Federal Reserve’s December meeting are due Tuesday, and markets are focused on what they signal about the pace of rate cuts in 2026 after the central bank lowered its benchmark rate by 75 basis points — or three-quarters of a percentage point — over its last three meetings to 3.50%–3.75%, Reuters reported. Reuters

On Friday, Caterpillar traded between $578.65 and $583.83, with about 954,000 shares changing hands, according to historical pricing data. FinancialContent

U.S. stocks finished marginally lower in a light-volume post-Christmas session with few catalysts, Reuters said, snapping a five-session rally even as major indexes stayed close to record territory. Reuters

The session also fell in the so-called “Santa Claus rally” window — the last five trading days of the year and the first two of the new year — a seasonal stretch traders watch for year-end strength. Reuters

Other industrial names were broadly steady. Deere rose 0.3%, Cummins gained 0.3% and Paccar added 0.2% on the day, according to market data.

Investors are also tracking whether market leadership keeps broadening beyond big technology, Reuters reported, after non-tech areas such as financials and transports outperformed tech in recent weeks. Reuters

“Handicapping how many rate cuts we’re going to get next year is a big thing markets are focused on right now,” Michael Reynolds, vice president of investment strategy at Glenmede, said. Reuters

Caterpillar, which sells construction and mining equipment and power systems and provides financing through its Financial Products segment, tends to be sensitive to both end-market demand and borrowing conditions for dealers and customers. Caterpillar Investors

Ahead of Monday’s open, traders will be watching for outsized swings tied to year-end portfolio adjustments, when lighter volumes can magnify moves, Reuters said. Reuters

On the chart, the stock has pulled back from a recent $627.50 high on Dec. 12 and rebounded from a Dec. 17 low of $557.46, putting the mid-$580s in focus going into the final trading days of the year. FinancialContent

Income-focused investors also have a date on the calendar: Caterpillar’s next ex-dividend date is Jan. 20, with a $1.51-per-share dividend payable Feb. 19, according to the company’s dividend history. Caterpillar Investors

Wall Street will also look ahead to fourth-quarter results, with MarketScreener listing a projected Q4 2025 earnings release on Jan. 28. Marketscreener

Stock Market Today

  • Mankind Pharma's Stock Decline Contrasts With Steady Financials and Industry-Matched Earnings Growth
    January 18, 2026, 7:36 PM EST. Mankind Pharma Limited's stock has fallen 11% in the past three months despite showing solid financial fundamentals. Its return on equity (ROE), a measure of profitability relative to shareholder investment, stands at 11%, closely aligned with the industry average of 12%. Over the past five years, the company achieved a 12% net income growth, mirroring sector performance. This suggests efficient management and a low payout ratio may be fueling growth despite a moderate ROE. The declining stock price might not fully reflect the company's decent earnings prospects and underlying stability. Investors should consider whether the market has fully priced in these factors when assessing Mankind Pharma's long-term potential.
Linde stock barely budges into year-end as Fed minutes loom
Previous Story

Linde stock barely budges into year-end as Fed minutes loom

Mastercard stock holds near $580 as Fed minutes loom and year-end trading thins
Next Story

Mastercard stock holds near $580 as Fed minutes loom and year-end trading thins

Go toTop